即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 近日，全球脊柱医疗器械公司 Accelus 宣布完成了 其最新一轮融资 ，具体融资金额和条款未公开披露。自公 司成立以来，Accelus已完成 四轮融资 。其中，最大的一轮融资是2024年1月完成的 2000万美元（约合1.4 亿元人民币）的债权融资 ，由Symbiotic Capital领投。 此外，Accelus 宣布任命医疗技术行业资深人士 Bernie Haffey 担任董事会主席 。 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 Haffey于2024年2月 加入Accelus董事会 ，并在2025年5月29日 被任命为董事会主席 ，接替Alex Lukianov。Haffey表示："我很荣幸担任Accelus的董事会主席，并期待与Kevin及董事会合作，加速公司成为 全球可扩展脊柱植入物市场的领导者。Accelus的创新技术和快速增长的市场地位使其处于有利位置，我致力 于通过引入HPMS框架，推动卓越文化和组织对齐，助力公司实现 ...

Core Insights - The article discusses the establishment of a strategic partnership between Siemens Healthineers and Massachusetts General Hospital (MGH) to create a Treatment Command Center aimed at integrating molecular imaging technology with targeted radiopharmaceutical therapy for precision diagnosis and personalized treatment [2][3][5]. Group 1: Partnership Overview - The Treatment Command Center's mission is to integrate molecular imaging technology, targeted radiopharmaceutical therapy, and real-time data analysis to create a comprehensive management system for diseases such as prostate cancer and neuroendocrine tumors [3][5]. - This collaboration marks a significant milestone in the long-standing partnership of 23 years between Siemens Healthineers and MGH, focusing on high-end imaging technology applications in neuroscience and oncology [6]. Group 2: Technological Innovations - The center relies on two revolutionary PET/CT devices: Biograph Vision Quadra and Biograph Trinion, which represent breakthroughs in both research-grade whole-body imaging and clinical efficiency [9]. - Biograph Vision Quadra is the world's first whole-body PET/CT using ultra-high-performance time-of-flight (TOF) technology, significantly improving image clarity while reducing patient radiation exposure to levels comparable to traditional chest X-rays [12]. - Biograph Trinion is designed for small to medium-sized hospitals, featuring a digital detector that reduces energy consumption by 46% and occupies 30% less space, making it a cost-effective choice for regional medical institutions [15]. Group 3: Clinical and Research Impact - The Treatment Command Center breaks traditional single-diagnosis models by integrating multidisciplinary collaboration, real-time data analysis, and intelligent treatment decision support systems, enhancing patient treatment efficiency [16]. - The center will collect multimodal data to support AI algorithm development and facilitate new targeted drug research, with a global multi-center study on prostate cancer PSMA treatment set to launch in 2025 [16]. Group 4: Market Dynamics - The global PET/CT market is characterized by a dual-track competition between international brands and domestic technologies, with GE Healthcare and Philips leading in innovation while domestic brands like United Imaging and Sino United Health are making significant advancements [17][22]. - GE Healthcare's Discovery series and Philips' Vereos Digital PET/CT are notable for their advancements in imaging quality and radiation dose reduction, catering to sensitive patient populations [19][21]. Group 5: Future Outlook - The Treatment Command Center plans to expand to more affiliated hospitals by 2026, aiming to serve over 2,000 patients and extend its model globally, including Europe and Asia, by 2028 [27]. - Siemens Healthineers aims to enhance its AI-driven treatment response prediction models by integrating more clinical and genomic data, promoting the widespread adoption of precision medicine beyond developed countries by 2030 [27].

Core Viewpoint - Ceryx Medical has successfully completed a $15 million funding round to advance the clinical research and miniaturization of its core product, the Cysoni bioelectronic pacemaker, which aims to address chronic heart failure by simulating natural heart rhythms [1][2]. Funding and Recognition - The recent $15 million financing is a critical part of Ceryx's three funding rounds, with previous rounds including £575,000 in seed funding in 2020 and £3.8 million in 2022 [2][5]. - Ceryx has received various accolades for its technological innovations, including the "Business Startup Award" from the Institute of Physics in the UK, and has collaborated with industry leader Osypka Medical for clinical validation [3]. Market Environment and Application Potential - Chronic heart failure (CHF) affects approximately 30 million patients globally and leads to over 1 million hospitalizations annually in Europe and the US, consuming more than 2% of national healthcare budgets [4]. - Despite existing treatments like CRT and ICD, nearly 50% of CHF patients face a mortality risk within five years of diagnosis, highlighting the need for improved therapeutic options [4]. Core Technology - Ceryx's Cysoni system aims to synchronize heart and respiratory rhythms, offering a novel intervention path that complements existing treatments [10]. - The technology is adaptable and could potentially be applied to other conditions such as hypertension, arrhythmias, and spinal cord injuries [10][13]. Clinical Progress - The Cysoni system has received approval from the UK MHRA in 2024 and is currently in the RSA-pace study phase, which evaluates its safety and efficacy in postoperative patients [15]. - A permanent implantable version, Cysoni-XT, is in development, with plans for broader clinical studies starting in 2025-2026 [15]. - Ceryx is also collaborating with Hydrix to develop a portable clinical trial system to enhance early human research efficiency [15]. Company Overview - Ceryx Medical was founded in 2016 and is based in Cardiff, UK, with a team that includes experts in artificial neurons and cardiac neurophysiology [16].

Group 1 - The article discusses the 2024 Global Medical Technology Innovation Awards and the 2024 Global Medical Technology Newcomer Awards, with a ceremony held on June 28 for companies included in the list for the first half of 2024 [1] - Companies that wish to participate in the 2025 awards ceremony on July 17 must fill out a registration form, and failure to participate will be considered as forfeiting the opportunity [1] - The awards are free of charge, but companies are responsible for their own travel expenses [1] Group 2 - The list of awarded companies for the 2024 Global Medical Technology Innovation Awards includes: Mindray Medical, MicroPort Medical, HeartSky Medical, Qiming Medical, Zhenyi Medical, and others [3] - The article provides a link for awarded companies to fill out their information for the awards [4] - The article encourages companies to actively participate in upcoming events organized by the company, including the Second Global Medical Technology Conference on July 17, 2025, and the Third Global Surgical Robot Conference from September 3-5, 2025 [5]

Core Insights - The article highlights the advancements of Nanjing Bosh Medical Technology Co., Ltd. in the field of ophthalmic devices, particularly through its innovative adaptive optics technology, which has been successfully commercialized after years of research and development [1][3][8] Company Overview - Nanjing Bosh Medical was established in 2017 and focuses on integrating optical engineering, adaptive optics, eye tracking, and AI algorithms into ophthalmic device development [1][3] - The company recently completed a Series C financing round to support product iteration, market expansion, and global layout in the ophthalmic diagnostic equipment sector [1][3] Technological Advancements - The adaptive optics technology, originally from astronomy, has been refined by Bosh Medical to achieve a device size reduction to 1/50 of traditional systems and a manufacturing cost reduction to 1/20, enabling commercial viability [3][4] - The "Star Mirror®" system developed by Bosh Medical offers a resolution of 0.7μm, which is nearly ten times better than conventional devices, allowing for detailed observation of retinal structures [3][4] Clinical Applications - The "Star Mirror®" system has been utilized in clinical settings to detect early cell loss in hereditary retinal diseases, providing timely intervention opportunities that traditional devices often miss [4][6] - The system also enables dynamic observation of retinal blood flow, offering critical insights for early diagnosis of vascular diseases like diabetic retinopathy [4][6] Product Matrix Development - Bosh Medical is building a comprehensive product matrix that includes diagnostic, treatment, and preventive solutions, such as the "Zhi Guang®" intelligent navigation laser device, which integrates real-time imaging and AI-assisted treatment planning [7][8] - The company aims to create a closed-loop system for eye health that addresses various age-related needs, reflecting a strategic shift from a single-technology focus to a comprehensive solution provider [7][8] Market Positioning - The ophthalmic medical device market is undergoing structural changes, with a significant unmet clinical demand due to a high prevalence of eye diseases and a lack of domestic alternatives to imported high-end equipment [8] - Bosh Medical's strategy emphasizes technological originality and a dual-track deployment model, focusing on top-tier research institutions and hospitals to validate its technology and establish academic credibility [8]

Core Insights - The article discusses the advancements and upcoming events in the field of ophthalmic surgery robotics, particularly focusing on the ORYOM™ platform developed by ForSight Robotics, which aims to address the challenges in cataract surgery through automation and precision [2][18]. Group 1: Industry Context - There are over 600 million cataract patients globally, with only about 30 million surgeries performed annually, indicating a significant gap in treatment availability [3]. - The supply of ophthalmologists is declining, with an expected 12% decrease in the number of doctors by 2035, while demand is projected to increase by 24% [3]. Group 2: Technological Advancements - The ORYOM™ platform is the first AI-based ophthalmic surgical robot, designed specifically for eye surgery, featuring micro-robots, AI algorithms, and intraoperative imaging systems [7][10]. - The platform has demonstrated high precision in animal models, completing cataract surgeries with an average time of 277 seconds and low complication rates [7][8]. Group 3: Clinical Development - ForSight Robotics has received ISO 13485 certification and plans to initiate its first human clinical trial in 2025, focusing on the safety and preliminary effectiveness of the ORYOM™ platform [16]. - The trial is expected to include 10-30 patients and will assess key metrics such as capsular integrity and intraocular lens centration [16]. Group 4: Future Directions - The company aims to standardize surgical procedures by programming optimal surgical action sequences, potentially reducing reliance on surgeon skill and enhancing safety [17]. - The ORYOM™ platform is uniquely designed for ophthalmic procedures, differentiating itself from existing surgical robots in other fields, and may become the first to enter human trials in ophthalmic surgery [18].

Core Viewpoint - GrOwnValve has developed a revolutionary self-growing heart valve, AdultValve, which utilizes the patient's own tissue, potentially transforming the treatment of heart valve diseases and reducing the need for multiple surgeries [7][19]. Company Overview - GrOwnValve was founded in 2019 by pediatric cardiologist Boris Schmitt and entrepreneur Jasper Emeis, based in Berlin, Germany. The company focuses on developing a revolutionary, self-growing, autologous transcatheter heart valve system [19]. Product Introduction - AdultValve is made from the patient's own pericardial tissue, designed using 3D imaging technology, and features a delivery system for minimally invasive implantation, avoiding open-heart surgery [11][13]. - The valve is expected to have superior biocompatibility and durability, eliminating issues related to calcification and dependence on anticoagulant medications [11][13]. Clinical Trials - The GECT-DZHK28 study, initiated by the German Center for Cardiovascular Research, aims to assess the safety and short-term efficacy of the GrOwnValve transcatheter pulmonary valve, particularly suitable for children as it can grow and remodel with the patient [15][17]. - The study has a budget of approximately €418,966 and aims to recruit 57 patients, with follow-ups every three months for five years [17][18]. Industry Context - Heart valve disease treatment has advanced significantly, but challenges remain regarding valve durability and long-term patient outcomes. There is a growing demand for safer, longer-lasting, and minimally invasive valve solutions, especially for younger patients [6][7].

Core Viewpoint - The article highlights the opening event of the Baidachu Aesthetic Medicine Concept Verification Center, emphasizing its role as a pioneering platform in China for the transformation of plastic surgery technology achievements [6]. Group 1: Event Details - The event is scheduled for June 27, 2025, from 14:00 to 16:00 at the Langcheng Building in Beijing [4]. - The expected scale of the event is around 20 participants, including medical aesthetic entrepreneurs, investors, and industry professionals [4]. - The agenda includes a center introduction, self-introductions, and a session for free communication [4][6]. Group 2: Center Overview - The Baidachu Aesthetic Medicine Concept Verification Center is the first specialized platform in China focusing on the transformation of plastic surgery scientific achievements [6]. - The center relies on the Chinese Academy of Medical Sciences Plastic Surgery Hospital and focuses on innovations related to materials, instruments, and drug-device combinations [6]. - It aims to provide support and collaboration networks for doctors, enterprises, and research teams from concept to product [6].

Core Viewpoint - The article emphasizes the importance of mature medical devices in China's healthcare system, highlighting the need for a new perspective on these products that are often overlooked despite their critical role in surgical efficiency, safety, and cost management [2][3][4]. Summary by Sections Industry Overview - The series aims to reassess products that are no longer considered "sexy" but are foundational to the Chinese medical system, focusing on their value, challenges, and potential [3][4]. Research Project - A long-term research project titled "Research on Mature Medical Device Tracks in China" has been initiated to systematically analyze mature products that are often taken for granted, revealing their true business logic and emerging structural opportunities [4][5]. Focus Product: Soft Tissue Ultrasound Knife - The first report in the series focuses on the soft tissue ultrasound knife, which is widely used in various minimally invasive surgeries and has transitioned from being dominated by imported brands to a rapidly growing domestic market [5][10]. - This product exemplifies a "mature but not yet concluded" category, having completed the transition from import to domestic production, with high penetration rates and essential demand in surgeries [5][10]. Key Insights from the White Paper - The white paper includes a comprehensive overview of over 20 major domestic and international manufacturers, detailing their certified products, technical features, and core strategies [8][11]. - It addresses critical questions such as market saturation, innovation opportunities post-price wars, potential for new entrants, and the prospects for companies in the post-collective procurement landscape [10][11]. Target Audience - The report is aimed at various stakeholders, including medical device companies, investment analysts, government teams, hospital procurement departments, and entrepreneurs focused on stable and certain market segments [12]. Future Outlook - The upcoming white paper titled "Opportunities in the Operating Room: Ultrasound Knife Industry White Paper (2024)" will be released soon, indicating that this is just the beginning of a broader analysis of other medical devices that may also have untold stories [15].

Core Viewpoint - The article highlights the significant advancements and funding achievements of Guangdong BoMai Medical Technology Co., Ltd. (BoMai Medical), emphasizing its leading position in the vascular intervention balloon catheter market and its potential for future growth through innovation and strategic partnerships [1][2][4]. Funding and Financial Growth - BoMai Medical completed a D-round financing of several hundred million RMB on June 18, 2025, led by IDG Capital, with participation from other notable investors [2][18]. - The company has successfully raised capital through five rounds of financing since 2014, indicating strong market confidence and support for its growth trajectory [18]. Industry Position and Product Development - Established in 2012, BoMai Medical is the largest manufacturer of vascular intervention balloon catheters in China, holding over 50% of the domestic market share and exporting more than 70% of its products [4][6]. - The company has developed over 40 product lines across four major areas: coronary intervention, peripheral intervention, vascular access, and neuro intervention, with more than 360 medical device registrations globally [4][6]. Technological Innovation - BoMai Medical's core technology focuses on balloon dilation catheters, which are essential for treating complex cardiovascular diseases [6][8]. - The company possesses over 150 intellectual property rights and has established a research center for vascular intervention technology, showcasing its commitment to innovation [8]. Market Potential and Competitive Landscape - The cardiovascular intervention device market in China was valued at approximately 37.2 billion RMB in 2021 and is projected to reach 140.2 billion RMB by 2030, with a compound annual growth rate (CAGR) of 15.88% [13][15]. - Despite the high market potential, the domestic market for balloon catheters remains largely dominated by foreign brands, presenting significant opportunities for BoMai Medical to capture market share through its innovative products [16]. Strategic Partnerships - In February 2025, BoMai Medical partnered with the international medical device company Cordis to localize the production of peripheral vascular drug-coated balloons, addressing a critical technological bottleneck in the industry [9][11].